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| INTRODUCTION
In this article, we review new developments in the areas of risk of venous thromboembolism (VTE) and VTE prevention in major orthopedic surgery. We discuss the changing epidemiology of VTE in patients undergoing major orthopedic surgery, risk factors for VTE and new developments in risk prediction, recommendations pertaining to the use of aspirin for VTE prophylaxis after major orthopedic surgery, and recent and ongoing aspirin trials. We focus on hip and knee joint arthroplasty surgery due to a relative lack of modern evidence pertaining to hip fracture surgery. We also touch on risk of VTE and guideline recommendations for VTE prevention in 2 other commonly encountered orthopedic populations for which clinical questions regarding thromboprophylaxis frequently arise: patients undergoing knee arthroscopy and those with distal leg fractures. Finally, we summarize relevant new data on this topic that were presented at the 2019 ISTH annual congress in Melbourne.
| HISTORICAL PERSPECTIVE
Patients undergoing orthopedic surgery have long been recognized to be at increased risk of VTE and were among the first patient group to be studied in VTE prophylaxis trials. 1 
| HOW COMMON IS VTE AFTER TOTAL HIP OR TOTAL KNEE ARTHROPLASTY?
Without pharmacologic thromboprophylaxis, rates of DVT detected with routine contrast venography were in the order of 54% after total hip arthroplasty (THA), of which 27% were proximal DVT, and 64% after total knee arthroplasty (TKA), of which 15% were proximal DVT. 2 However, rates of symptomatic VTE, which refer to those that present with patient symptoms, rather than those detected with routine screening tests in asymptomatic patients, are far lower.
Symptomatic VTE, which are considered outcomes of greater clinical importance to patients, occur in the range of ~2% to 3% after THA without pharmacologic prophylaxis and ~1% to 1.2% (THA: DVT 0.7%, pulmonary embolism [PE] 0.3%; TKA: DVT 0.9%, PE 0.3%) with pharmacologic prophylaxis. [3] [4] [5] [6] 
| BALANCING VTE AND BLEEDING: DO THE BENEFITS OF THROMBOPROPHYLAXIS ALWAYS OUTWEIGH THE RISKS?
Recently, Chan et al conducted a systematic review of randomized trials that compared different pharmacologic thromboprophylaxis regimens (apixaban, dabigatran, enoxaparin, fondaparinux, rivaroxaban) in THA or TKA patients, with a focus on the outcomes of symptomatic VTE, major bleeding, clinically relevant nonmajor bleeding and mortality. 7 Various definitions of major bleeding and clinically relevant nonmajor bleeding were used in the individual trials. 8, 9 In total, 40 285 patients were included. Results showed that across trials, symptomatic VTE occurred on average in about 1% of patients, and the average rate of VTE was similar to or exceeded by the average rate of major bleeding, which occurred in 0.5% to 2% of patients and up to 4% to 5% of patients, if major bleeding and clinically relevant nonmajor bleeding, including surgical site bleeds, are combined.
This raises the question of whether our focus has been too much on thrombosis at the expense of bleeding complications and, by extension, that risk stratification of orthopedic surgery patients may be the key to achieving the ideal risk-benefit ratio and applying best options for safe and effective thromboprophylaxis. This is especially relevant as trends over time suggest that rates of VTE after major orthopedic surgery may be decreasing.
| EPIDEMIOLOGY AND TRENDS OVER TIME IN VTE OCCURRENCE AFTER MAJOR ORTHOPEDIC SURGERY
An important aspect of the epidemiology of VTE after major orthopedic surgery, reported more than 20 years ago, is that most cases occurred after hospital discharge. White and colleagues showed in 1998 that patients undergoing THA and TKA remained at risk of VTE for weeks after surgery. 10 Using the California discharge database, the median time to VTE was 17 days in 19 586 patients undergoing THA and 7 days in 24 059 patients undergoing TKA, and many of these events (76% after THA and 47% after TKA) occurred after hospital discharge. Of note, mean length of stay in that study for both THA and TKA was ~7 days but is much shorter now. These data provided the impetus for numerous clinical trials evaluating postdischarge, extended-duration thromboprophylaxis, compared with prophylaxis restricted to the duration of hospital stay. Results of these trials have informed guideline panels to recommend extended duration prophylaxis (up to 28-35 days) after major orthopedic surgery. 5, 11, 12 Recent studies have suggested that overall rates of VTE after major orthopedic surgery are falling. A study from a national database from England and Wales of 10-year trends (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) in medical complications in 540 623 patients undergoing THA found that despite a population with increasing levels of comorbidity, the 90-day mortality rate decreased from 0.60% to 0.15%, the 30-day DVT rate decreased from 1.15% to 0.28%, and the 30-day PE rate decreased from 0.77% to 0.40%. 13 A recent systematic review of 255 studies that included almost 6.3 million patients found a consistent decline in mortality within 3 months after elective THA or TKA (from 1.15% pre-1980 to 0.24% post-2000) that was independent of method of prophylaxis. 14 
Why
have rates of VTE and mortality decreased? This is likely due to some combination of improvements in surgical techniques and perioperative care, including unicompartmental surgery, shorter operative procedure times, greater use of regional anesthesia, more effective analgesia, faster postoperative mobilization, increased use of day-case procedures, shorter duration of hospitalization, and more consistent use and/or longer duration of prophylaxis. 15 
| WHAT ABOUT MOVING BACK TO SHORTER DURATIONS OF PROPHYLAXIS?
In view of trends over time toward decreasing rates of VTE in patients with major orthopedic surgery, what about moving back to shorter durations of prophylaxis, for at least some patients, such as had lengths of stay ≤5 days (median, 2 days) and had in-hospital anticoagulant prophylaxis only; no mechanical prophylaxis was used.
Mean age was 67 years. The incidence of symptomatic VTE within 90 days was low, at 0.40% (0.16% PE, 0.22% DVT, 0.02% combined DVT and PE). Two PEs (0.01%) were fatal. Risk factors for VTE were aged >85 years and body mass index (BMI) >35 kg/m 2 . 16 While this was not a randomized controlled trial, results suggested that thromboprophylaxis after discharge may not be necessary in fast-track THA and TKA with length of stay of ≤5 days. Further studies, ideally randomized controlled trials, are needed to assess the safety of this approach, especially in higher-VTE-risk fast-track patients.
What does this mean for our orthopedic surgery patients? On the one hand, these patients are at increased risk for VTE, and risk persists for weeks after surgery, which is why extended-duration prophylaxis is guideline recommended. On the other hand, the average risk of VTE after major orthopedic surgery may be decreasing over time and is similar to or may be lower than the risk of bleeding with pharmacologic thromboprophylaxis. Further, shortened duration prophylaxis for lower-VTE-risk patients having fast-track orthopedic procedures may prove, with further study, to be effective.
The key to optimizing prophylaxis in this patient group is better risk stratification, as discussed below.
| CONCEPT OF POPULATION VERSUS INDIVIDUAL APPROACH TO PROPHYLAXIS
To date, the literature, including guidelines, has primarily focused on using a population (sometimes called whole group) approach to orthopedic surgery thromboprophylaxis. The population approach is based on the concept that for major orthopedic surgery, surgery-attributed risk far outweighs the contribution of patientspecific risk factors; thus, surgery itself guides prophylaxis decisions. The advantages of this approach is that it simplifies practice and increases the likelihood of implementation. However, an individual approach is increasingly appealing; its concept is that the individual's risk of developing VTE (and bleeding) should be assessed and used to guide individual prophylaxis decisions. Ideally, this approach should use validated risk assessment models (RAMs) specific to patients undergoing orthopedic surgery, similar to risk stratification and RAMs recommended by various national and international guidelines for use in hospitalized medical and nonorthopedic surgical patients. [17] [18] [19] [20] An individual approach to prophylaxis would take into account patient risk factors for VTE and bleeding in addition to the surgery itself to help guide prophylaxis decisions.
| INDIVIDUAL RISK FACTORS FOR VTE AFTER MAJOR ORTHOPEDIC SURGERY
What is known about risk factors for VTE in patients undergoing major orthopedic surgery? As shown in Table 1 Although there was no information on use of thromboprophylaxis, one would predict universal use of prophylaxis in major orthopedic surgery patients. These data suggest that our current prophylaxis approach to patients undergoing major orthopedic surgery with prior VTE may be inadequate; namely, such patients may require an increased dose and/or duration of thromboprophylaxis.
However, this requires study in well-designed randomized trials that assess both the efficacy and safety of more aggressive prophylaxis approaches.
| COMBINING RISK FACTORS INTO RISK ASSESSMENT MODELS IN THA OR TKA

Some investigators have tried to develop dedicated orthopedic
RAMs, specific to surgical intervention. In a recent systematic review, 5 VTE risk prediction scores in patients undergoing THA or TKA were identified; the number of component variables in the scores ranged from 5 to 26 (Table 2) . 23 While this work on RAMs is promising, the review identified several limitations. Some scores were developed using inadequate methodology, were inadequately reported, or were insufficiently validated. No RAM has been independently validated or used in a prospective impact study; thus, impact on patient outcomes and decision making is unknown.
Additional research is needed before RAMs can be used to guide VTE prophylaxis decisions in patients undergoing major orthopedic surgery.
As important as predicting risk of VTE is predicting risk of bleeding. However, there are no bleeding RAMs that have been sufficiently validated in orthopedic surgery populations. The American 
| ROLE OF ASPIRIN FOR VTE PROPHYLAXIS IN MAJOR ORTHOPEDIC SURGERY
The pragmatic advantages of aspirin for VTE prophylaxis are numerable; it is inexpensive, oral, widely available, easy to use, and potentially has a lower risk of bleeding than anticoagulant prophylaxis.
Some older studies (primarily the Pulmonary Embolism
Prevention [PEP] trial 24 ) suggested that aspirin used for 35 days was effective for VTE prophylaxis in hip fracture and patients undergoing THA, when compared to placebo. In the 2012 ACCP as an option for thromboprophylaxis after TKA (for 14 days), but for THA 10 days of LMWH is recommended before use of aspirin alone for an additional 28 days. 19 Hence, aspirin used alone may have a role to play in orthopedic prophylaxis, and guidelines are suggesting its use, albeit tentatively and with provisos, based on the low certainty of the evidence.
Higher-quality evidence is needed.
| THE EPCAT II TRIAL (ASPIRIN OR RIVAROXABAN FOR VTE PROPHYLAXIS AFTER HIP OR KNEE ARTHROPLASTY)
A recent large Canadian trial examined an interesting hybrid approach to using aspirin for VTE prophylaxis after major orthopedic surgery. The Extended Venous Thromboembolism Prophylaxis
Comparing Rivaroxaban to Aspirin Following Total Hip and Knee Arthroplasty (EPCAT II) trial was a multicenter, double-blind noninferiority randomized trial that enrolled patients undergoing elective unilateral THA or TKA. 26 Postoperatively, all participants received oral rivaroxaban 10 mg daily for 5 days, and were then randomized to either continue oral rivaroxaban 10 mg daily (control group) or to take oral aspirin 81 mg daily (intervention group)
for an additional 30 days in patients undergoing THA and an additional 9 days in patients undergoing TKA. Participants were followed for 90 days. The trial was a noninferiority design based on a 1.0% control group event rate and a 1% minimal clinically important difference.
In total, 3424 patients were enrolled in the trial. Results showed that aspirin was noninferior to rivaroxaban, with symptomatic VTE (including symptomatic PE, proximal DVT, or both) occurring in 0.64% and 0.70% of participants, respectively (P = .84; P < .001
for noninferiority). Results were similar in analyses stratified by sur- After the EPCAT II trial was published, orthopedic surgeons and thrombosis physicians met at one of our centers and agreed on using the risk assessment approach shown in Figure 1 , which takes into account patient-specific risk factors for VTE, inclusion and exclusion criteria of the EPCAT II trial, and baseline characteristics of EPCAT II participants. If adopted in other centers, it is important for each center to establish who will conduct this risk assessment (eg, orthopedic resident, surgeon, or nurse; internal medicine or thrombosis consultant), and when and where it will be conducted (eg, preoperatively in the clinic, preoperatively in the hospital, postoperatively).
Thus, pending the results of ongoing aspirin trials (described below), our approach is to use the hybrid prophylaxis protocol studied in EPCAT II for lower risk patients (patients similar to those enrolled in EPCAT II), and preferentially use anticoagulant prophylaxis (and not aspirin alone) in all other patients undergoing THA or TKA who are eligible to receive pharmacologic thromboprophylaxis. We use mechanical prophylaxis for those who are at risk of bleeding or are bleeding.
| ONGOING ASPIRIN TRIALS
Building on the available evidence base on the use of aspirin for major orthopedic surgery thromboprophylaxis, the next logical step is to study the use of aspirin alone as solo prophylaxis. Two large trials are under way: Joint function and patient well-being will also be assessed. The study is expected to be completed in 2021. The study is expected to be completed in 2024.
The Comparative Effectiveness of Pulmonary Embolism Prevention
The
| ADDITIONAL ORTHOPEDIC SURGERY TOPICS: KNEE ARTHROSCOPY AND DISTAL LEG FRACTURES
Below, we discuss the level of VTE risk in 2 commonly encountered orthopedic populations, those undergoing knee arthroscopy and those with distal leg fractures; review guideline recommendations; and present our own approach to thromboprophylaxis in these patients.
| RISK OF VTE AFTER KNEE ARTHROSCOPY
Based on data from a number of large, population-based studies, the occurrence of VTE after knee arthroscopy is infre-
quent (<0.5%) for most patients. A recent UK National Health
Service study of severe adverse outcomes of arthroscopic surgery in 700 000 patients described a 0.08% rate of any PE and a 0.001% rate of fatal PE within 90 days. 27 A Kaiser Permanente study of more than 20 000 patients undergoing knee arthroscopy described a 0.25% rate of DVT and a 0.17% rate of PE. 28 An American College of Surgeons National Surgical Quality Improvement Program study (N = 12 271) found DVT rates of 0.46% and PE rates of 0.05% within 30 days after knee arthroscopy, 29 and a Mayo Clinic Olmsted County study (N = 4833)
reported DVT rates of 0.36% and PE rates of 0.04%; all events F I G U R E 1 Suggested risk stratification for hybrid DOAC/aspirin prophylaxis after total hip arthroplasty or total knee arthroplasty*. *Hybrid DOAC/aspirin prophylaxis = DOAC at prophylaxis dose (rivaroxaban 10 mg orally daily was used in EPCAT II trial) for 5 days, followed by aspirin 81 mg orally daily for 30 days (patients undergoing THA) or 9 days (patients undergoing TKA 1.7) . The importance of previous VTE as a risk factor was further emphasized by a recent report from the MEGA study, which showed that patients with previous VTE who subsequently required lower leg casting had a 4.5-fold risk of developing recurrent VTE, which translated to an absolute risk of 3.2% within 3 months. 35 A meta-analysis of 15 studies reporting outcome data on 80 678 patients found that only advancing age and injury type were predictive of VTE and cautioned against using individual risk factors to guide the use of thromboprophylaxis. 36 However, prospective validation, ideally with implementation studies, are required.
| EFFECTIVENESS OF THROMBOPROPHYLAXIS AFTER KNEE ARTHROSCOPY OR LOWER LEG CASTING
The Thrombosis Prophylaxis After Knee Arthroscopy (POT-
KAST) and Thrombosis Prophylaxis During Plaster Cast Lower Leg
Immobilization (POT-CAST) randomized controlled trials assessed the effectiveness and safety of LMWH versus placebo given for 8 days after knee arthroscopy (n = 1451) or for the full period of immobilization after lower leg casting (n = 1435). 40 Results showed that VTE prophylaxis with LMWH was ineffective after knee arthroscopy or lower leg casting. In the POT-KAST trial, 0.7% randomized to LMWH versus 0.4% randomized to placebo developed VTE (RR, 1.6; 95% CI, 0.4-6.8), with very low rates of major bleeding (0.1% in both groups). In the POT-CAST trial, 1.4% randomized to LMWH versus 1.8% randomized to placebo developed VTE (RR, 0.8;
95% CI, 0.3-1.7), with no episodes of major bleeding in either group.
Overall rates of VTE were low in all groups, consistent with the observational data presented above; however, it should be noted that patients with a history of VTE were excluded from participation in the 2 trials.
A subsequent secondary analysis of the POT-CAST trial identified that while BMI >30 kg/m 2 , family history of VTE, Achilles tendon rupture, and surgical treatment of traumatic leg injury increased VTE risk, thromboprophylaxis remained ineffective in these highrisk subgroups. 38 Recently, a 2019 meta-analysis reviewed 13 randomized trials (6857 participants) that compared thromboprophylactic agents to each other or to no pharmacologic prophylaxis to prevent VTE in patients with temporary lower-limb immobilization after injury. 41 
| WHAT DO THE GUIDELINES RECOMMEND?
| For patients with isolated distal leg fracture and immobilization
The 2012 ACCP guidelines suggest no prophylaxis rather than pharmacologic prophylaxis (Grade 2B). 5 The 2018 European Society of Anaesthesiology (ESA) guidelines recommend no pharmacologic VTE prevention in patients without high VTE risk (Grade 1C), and suggest using aspirin for VTE prevention after low-risk orthopedic procedures in patients with high VTE risk (Grade 2C). 42 The 2019
ASH guidelines do not address this patient group.
| For patients undergoing knee arthroscopy
The 2012 ACCP guidelines suggest no prophylaxis rather than pharmacologic prophylaxis in patients without a history of VTE (Grade 2B). 5 The 2018 ESA guidelines recommend no pharmacologic VTE prevention after low-risk orthopedic procedures (eg, knee arthroscopy) in patients without high VTE risk (Grade 1C), and suggest aspirin for VTE prevention in patients with high VTE risk (Grade 2C). 42 The 2019 ASH guidelines do not address this patient group. 
| OUR APPROACH
| ISTH MELBOURNE REPORT
A number of abstracts relating to VTE risk and risk prediction after orthopedic surgery were presented at ISTH Melbourne. 
F I G U R E 2
Individualized approach
The risk of VTE after different types of orthopedic surgery and the additional effect of genetic risk factors for VTE were estimated in an interesting analysis of the MEGA study by Zambelli et al. 43 Overall, orthopedic surgery was associated with an increased risk of VTE, which was highest in the first 30 days postoperatively (OR, 17.5) but remained high even as long as 1 year after surgery (OR, 3.7).
The risk was further enhanced in patients with the factor V Leiden mutation, non-O blood type, and elevated factor VIII levels. Spine, knee, and below-knee surgeries were associated with the highest risk for VTE, while patients who had hip or upper-limb surgery had a lower but still increased risk. In a retrospective study of patients undergoing TKA who received rivaroxaban prophylaxis, Mian and factor IX, factor XI, von Willebrand factor, fibrinogen and D-dimer did not increase postoperatively in patients who had knee arthroscopy; thus, the increased risk of thrombosis after knee arthroscopy does not appear to relate to levels of these procoagulant factors. 47 Finally, while participants with lower-leg trauma had evidence of increased thrombin generation compared to a group of random controls, results of the thrombin generation assay were not useful to identify patients who developed VTE after lower-leg trauma or knee arthroscopy. 48 
| CONCLUSION AND FUTURE DIRECTIONS
The epidemiology of VTE after major orthopedic surgery is changing, and VTE risk in many patients is lower than in previous decades.
While rates of VTE may be decreasing overall, some patients (particularly those with prior VTE) remain at increased risk.
There is a shifting landscape in major orthopedic surgery prophylaxis ( Figure 2 ). From the late 1950s to the 2010s, trials tended to focus on venographic DVT, assessing prophylaxis in all patients based on a population approach. In general, anticoagulants were favored over mechanical prophylaxis or aspirin, and longer-duration prophylaxis was favored over shorter durations. More recently, orthopedic prophylaxis is starting to become more nuanced and individualized. Modern trials are focusing on symptomatic VTE as outcomes, and there has been a slow move to studying and recommending thromboprophylaxis based on individual attributes of patients, in whom risk stratification and weighing of benefit versus risk is becoming key. This reflects a shift from a population approach to an individual approach to prophylaxis.
Optimal choices for VTE prophylaxis (drug, duration) in patients undergoing THA and TKA are evolving. Interest in aspirin as a means of prophylaxis has resurged, and ongoing large clinical trials will help define optimal aspirin prophylaxis for patients undergoing THA and TKA. In the meantime, based on EPCAT II trial data, we believe that standard-VTE-risk patients undergoing THA and TKA can be considered for a hybrid approach (initial DOAC prophylaxis followed by extended-duration aspirin prophylaxis), while higher-VTE-risk patients should still receive extended-duration anticoagulant prophylaxis. VTE prophylaxis is not guideline recommended in patients undergoing standard-risk knee arthroscopy or patients with a lower-leg fracture, but our practice is always to inquire about prior VTE and other highrisk features that may warrant prophylaxis on an individual basis.
In terms of research priorities, validated RAMs are needed to individualize decision making in patients undergoing orthopedic surgery, followed by implementation studies of individualized treatment based on level of risk. This will enable us to identify lowrisk orthopedic patients who do not require thromboprophylaxis, as well as high-risk patients who may require higher doses and increased duration of prophylaxis. Research on thromboprophylaxis in hip fracture surgery is also needed. Finally, while beyond the scope of this article, studies of new thromboprophylaxis agents with more favorable risk-benefit profiles are awaited with great interest.
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